Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure

Drug and Alcohol Dependence

Volumn 76, Issue 2, 2004, Pages 181-190

  Gonzalez, Raul ^a,b   Rippeth, Julie D ^a,b   Carey, Catherine L ^a,b   Heaton, Robert K ^a,b   Moore, David J ^a,b   Schweinsburg, Brian C ^a,b,c   Cherner, Mariana ^a,b   Grant, Igor ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Cannabis; Cognitive effects; Marijuana; Methamphetamine; Neuroprotection; Neuropsychology

Indexed keywords

CANNABIS; METHAMPHETAMINE;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; TASK PERFORMANCE;

ADULT; AMPHETAMINE-RELATED DISORDERS; BRAIN; CANNABINOIDS; COGNITION; COMORBIDITY; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; METHAMPHETAMINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; PSYCHOMETRICS;

CANNABIS; CANNABIS SATIVA;

EID: 5644271850     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2004.04.014     Document Type: Article

References (69)

1. Abood M.E., Rizvi G., Sallapudi N., McAllister S.D. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309:2001;197-201
2. Army Individual Test Battery, 1944. Manual of directions and scoring. War Department, Adjutant General's Office, Washington, DC.
3. Benedict R.H.B., Schretlen D., Groninger L., Brandt J. Hopkins Verbal Learning Test - Revised: normative data and analysis of inter-form and test-retest reliability. Clin. Neuropsychol. 12:1998;43-55
4. Benedict R.H.B., Schretlen D., Groninger L., Dobraski M. Revision of the Brief Visuospatial Memory Test: studies of normal performance, reliability, and validity. Psychol. Assess. 8:1996;145-153
5. Borkowski J.G., Benton A.L., Spreen O. Word fluency and brain damage. Neuropsychologia. 5:1967;135-140
6. Carey, C.L., Woods, S.P., Gonzalez, R., Conover, E., Marcotte, T.D., Grant, I., Heaton, R.K., the HNRC Group, in press. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J. Clin. Exp. Neuropsychol.
7. Davidson C., Gow A.J., Lee T.H., Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Rev. 36:2001;1-22
8. Diehr M.C., Heaton R.K., Miller W., Grant I. The Paced Auditory Serial Addition Task (PASAT): norms for age, education, and ethnicity. Assessment. 5:1998;375-387
9. Ernst T., Chang L., Leonido-Yee M., Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology. 54:2000;1344-1349
10. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B., 1996. Structured clinical interview for DSM-IV Axis I disorders. Biometrics Research Department, New York.
11. Fride E., Shohami E. The endocannabinoid system: function in survival of the embryo, the newborn and the neuron. NeuroReport. 13:2002;1833-1841
12. Frost D.O., Cadet J.L. Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: a hypothesis. Brain Res. Rev. 34:2000;103-118
13. Gladsjo J.A., Schuman C.C., Evans J.D., Peavy G.M., Miller S.W., Heaton R.K. Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment. 6:1999;147-178
14. Gonzalez R., Carey C., Grant I. Nonacute (residual) neuropsychological effects of cannabis use: a qualitative analysis and systematic review. J. Clin. Pharmacol. 42(S):2002;48S-57S
15. Gonzalez R., Heaton R.K., Moore D.J., Letendre S., Ellis R.J., Wolfson T., Marcotte T., Cherner M., Rippeth J., Grant I. the HNRC Group Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J. Int. Neuropsychol. Soc. 8:2003;64-71
16. Grant I., Gonzalez R., Carey C., Natarajan L., Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J. Int. Neuropsychol. Soc. 9:2003;679-689
17. Gouzoulis-Mayfrank E., Schreckenberger M., Sabri O., Arning C., Thelen B., Spitzer M., Kovar K.A., Hermle L., Bull U., Sass H. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and D-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 20:1999;565-581
18. Gronwall D.M. Paced auditory serial-addition task: a measure of recovery from concussion. Percept. Mot. Skills. 44:1977;367-373
19. Guzman M., Sanchez C., Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 78:2001;613-625
20. Halstead, W.C., 1947. Brain and intelligence. University of Chicago Press, Chicago.
21. Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A. 95:1998;8268-8273
22. Hampson A.J., Grimaldi M., Lolic M., Wink D., Rosenthal R., Axelrod J. Neuroprotective antioxidants from marijuana. Ann. N. Y. Acad. Sci. 899:2000;274-282
23. Heaton R.K., Grant I., Butters N., White D.A., Kirson D., Atkinson J.H., McCutchan J.A., Taylor M.J., Kelly M.D., Ellis R.J., Wolfson T., Velin R., Marcotte T.D., Hesselink J.R., Jernigan T.L., Chandler J., Wallace M., Abramson I. the HNRC Group The HNRC 500 - Neuropsychology of HIV infection at different disease stages. J. Int. Neuropsychol. Soc. 1:1995;231-251
24. Heaton, R.K., Grant, I., Matthews, C.G., 1991. Comprehensive norms for an expanded Halstead-Reitan Battery: demographic corrections, research findings, and clinical applications. Psychological Assessment Resources Inc., Odessa, FL.
25. Heaton, R.K., Kirson, D., Velin, R.A., Grant, I., the HNRC Group, 1994. The utility of clinical ratings for detecting cognitive change in HIV infection. In: Grant, I., Martin, A. (Eds.), Neuropsychology of HIV Infection. Oxford University Press, New York, pp. 188-206.
26. Heaton, R.K., Taylor, M.J., Manly, J.J., 2002. Demographic effects and use of demographically corrected norms with the WAIS-III and WMS-III. In: Tulsky, D., Saklofske, D., Heaton, R.K., Chelune, G., Ivnik, R., Bornstein, R.A., Prifitera, A., Ledbetter, M. (Eds.), Clinical Interpretation of the WAIS-III and WMS-III. Academic Press, San Diego, CA.
27. Iyo M., Namba H., Yanagisawa M., Hirai S., Yui N., Fukui S. Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT. Prog. Neuropsychopharmacol. Biol. Psychiatry. 21:1997;789-796
28. Kleven M.S., Seiden L.S. Methamphetamine-induced neurotoxicity: structure activity relationships. Ann. N. Y. Acad. Sci. 654:1992;292-301
29. Kløve, H., 1963. Clinical neuropsychology. In: Forster, F.M. (Ed.), The Medical Clinics of North America. Saunders, New York.
30. Knoller N., Levi L., Shoshan I., Reichenthal E., Razon N., Rappaport Z.H., Biegon A. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit. Care Med. 30:2002;548-554
31. Lavie G., Teichner A., Shohami E., Ovadia H., Leker R.R. Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Brain Res. 901:2001;195-201
32. Leker R.R., Shohami E., Abramsky O., Ovadia H. Dexanabinol: a novel neuroprotective drug in experimental focal cerebral ischemia. J. Neurol. Sci. 162:1999;114-119
33. Louw D.F., Yang F.W., Sutherland G.R. The effect of delta-9- tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. 857:2000;183-187
34. Marshall J.F., O'Dell S.J., Weihmuller F.B. Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. J. Neural Transm. 91:1993;241-254
35. Marsicano G., Moosmann B., Hermann H., Lutz B., Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80:2002;448-456
36. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 18:1998;8417-8422
37. Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot. Essent. Fatty Acids. 66:2002;93-99
38. Mechoulam R., Panikashvili D., Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8:2002a;58-61
39. Mechoulam, R., Spatz, M., Shohami, E., 2002b. Endocannabinoids and neuroprotection Sci. STKE. 2002, RE5.
40. Nadler V., Mechoulam R., Sokolovsky M. The non-psychotropic cannabinoid (+)-(3S, 4S)-7-hydroxy-delta 6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci. Lett. 162:1993;43-45
41. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., Greenberg D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19:1999;2987-2995
42. Ohmori T., Abekawa T., Koyama T. The role of glutamate in behavioral and neurotoxic effects of methamphetamine. Neurochem. Int. 29:1996;301-307
43. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 413:2001;527-531
44. Pope H.G. Jr., Gruber A.J., Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 38:1995;25-34
45. Rippeth J., Heaton R.K., Carey C.L., Marcotte T.D., Moore D.J., Gonzalez R., Wolfson T., Grant I. the HNRC group Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J. Int. Neuropsychol. Soc. 10:2004;1-14
46. Robins, L.N., Cottler, L.B., Bucholz, K.K., Compton, W.M., North, C.S., Rourke, K.M., 1999. Diagnostic Interview Schedule for DSM-IV. Washinton University School of Medicine, St. Louis, Missouri.
47. Rumbaugh C.L., Bergeron R.T., Scanlan R.L., Teal J.S., Segall H.D., Fang H.C., McCormick R. Cerebral vascular changes secondary to amphetamine abuse in the experimental animal. Radiology. 101:1971;345-351
48. Rumbaugh C.L., Fang H.C., Wilson G.H., Higgins R.E., Mestek M.F. Cerebral CT findings in drug abuse: clinical and experimental observations. J. Comput. Assist. Tomogr. 4:1980;330-334
49. Segal D.S., Kuczenski R. An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics. J. Neurosci. 17:1997a;2551-2566
50. Segal D.S., Kuczenski R. Repeated binge exposure to amphetamine and methamphetamine: behavioral and neurochemical characterization. J. Pharmacol. Exp. Ther. 282:1997b;561-573
51. Seiden L.S., Sabol K.E. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res. Monogr. 163:1996;251-276
52. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., Takei N., Mori N. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am. J. Psychiatry. 158:2001;1206-1214
53. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:1996;4322-4334
54. Shen M., Thayer S.A. The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 783:1998a;77-84
55. Shen M., Thayer S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54:1998b;459-462
56. Simon S.L., Domier C., Carnell J., Brethen P., Rawson R., Ling W. Cognitive impairment in individuals currently using methamphetamine. Am. J. Addict. 9:2000;222-231
57. Simon S.L., Domier C.P., Sim T., Richardson K., Rawson R.A., Ling W. Cognitive performance of current methamphetamine and cocaine abusers. J. Addict. Dis. 21:2002;61-74
58. Sinor A.D., Irvin S.M., Greenberg D.A. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 278:2000;157-160
59. Spitzer, R.L., Williams, J.B., Gibbon, M., 1987. Structured clinical interview for DSM-III-R personality disorders. Biometrics Research Department, New York.
60. Stephans S.E., Yamamoto B.K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse. 17:1994;203-209
61. Substance Abuse and Mental Health Services Administration, 2001. Summary of findings from the 2000 national household survey on drug abuse. Office of Applied Studies, Rockville, MD.
62. van der Stelt M., Veldhuis W.B., Bar P.R., Veldink G.A., Vliegenthart J.F., Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 21:2001a;6475-6479
63. van der Stelt M., Veldhuis W.B., van Haaften G.W., Fezza F., Bisogno T., Bar P.R., Veldink G.A., Vliegenthart J.F., Di Marzo V., Nicolay K. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21:2001b;8765-8771
64. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Wong C., Logan J. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am. J. Psychiatry. 158:2001a;383-389
65. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry. 158:2001b;377-382
66. Wechsler, D., 1997. Wechsler Adult Intelligence Scale - Third Edition (WAIS-III). The Psychological Corporation, San Antonio, TX.
67. Wilkinson, G.S., 1993. The Wide Range Achievement Test - Third Edition. Wide Range Inc., Wilmington, DE.
68. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2:1996;699-703
69. Yamamoto B.K., Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharmacol. Exp. Ther. 287:1998;107-114